Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1993 to 1995 of 1995 entries
Sorted by: Best Match Show Resources per page
MYC-PDL1 axis reduces sensitivity to nivolumab in recurrent head and neck squamous cell carcinoma.

Oral oncology

Noji R, Kano Y, Hirai H, Onishi I, Nishii N, Yoshimura R, Miyake S, Ikeda S, Harada H.
PMID: 34896892
Oral Oncol. 2021 Dec 09;124:105666. doi: 10.1016/j.oraloncology.2021.105666. Epub 2021 Dec 09.

Patients with recurrent or metastatic squamous cell carcinoma of the head and neck (R/M HNSCC) have a poor prognosis. Recently, the use of immune checkpoint inhibitors (ICIs) for drug treatment has been expanding . However, the response rate to...

Cite
Noji R, Kano Y, Hirai H, et al. MYC-PDL1 axis reduces sensitivity to nivolumab in recurrent head and neck squamous cell carcinoma. Oral Oncol. 2021;124:105666doi: 10.1016/j.oraloncology.2021.105666.
Noji, R., Kano, Y., Hirai, H., Onishi, I., Nishii, N., Yoshimura, R., Miyake, S., Ikeda, S., & Harada, H. (2021). MYC-PDL1 axis reduces sensitivity to nivolumab in recurrent head and neck squamous cell carcinoma. Oral oncology, 124105666. https://doi.org/10.1016/j.oraloncology.2021.105666
Noji, Rika, et al. "MYC-PDL1 axis reduces sensitivity to nivolumab in recurrent head and neck squamous cell carcinoma." Oral oncology vol. 124 (2021): 105666. doi: https://doi.org/10.1016/j.oraloncology.2021.105666
Noji R, Kano Y, Hirai H, Onishi I, Nishii N, Yoshimura R, Miyake S, Ikeda S, Harada H. MYC-PDL1 axis reduces sensitivity to nivolumab in recurrent head and neck squamous cell carcinoma. Oral Oncol. 2021 Dec 09;124:105666. doi: 10.1016/j.oraloncology.2021.105666. Epub 2021 Dec 09. PMID: 34896892.
Copy Download .nbib Format: NLM
Phase I study of weekly nab-paclitaxel plus carboplatin and concurrent thoracic radiotherapy in elderly patients with unresectable locally advanced non-small cell lung cancer.

Investigational new drugs

Omori S, Harada H, Mori K, Hisamatsu Y, Tsuboguchi Y, Yoshioka H, Morinaga R, Daga H, Kurata T, Takahashi T.
PMID: 34495421
Invest New Drugs. 2022 Feb;40(1):106-114. doi: 10.1007/s10637-021-01155-w. Epub 2021 Sep 08.

Few clinical studies have been designed for elderly patients with locally advanced non-small cell lung cancer (NSCLC). We conducted a phase I study to evaluate the tolerability of carboplatin/nab-paclitaxel and concurrent thoracic radiotherapy in elderly patients with locally advanced...

Cite
Omori S, Harada H, Mori K, et al. Phase I study of weekly nab-paclitaxel plus carboplatin and concurrent thoracic radiotherapy in elderly patients with unresectable locally advanced non-small cell lung cancer. Invest New Drugs. 2021;40(1):106-114doi: 10.1007/s10637-021-01155-w.
Omori, S., Harada, H., Mori, K., Hisamatsu, Y., Tsuboguchi, Y., Yoshioka, H., Morinaga, R., Daga, H., Kurata, T., & Takahashi, T. (2022). Phase I study of weekly nab-paclitaxel plus carboplatin and concurrent thoracic radiotherapy in elderly patients with unresectable locally advanced non-small cell lung cancer. Investigational new drugs, 40(1), 106-114. https://doi.org/10.1007/s10637-021-01155-w
Omori, Shota, et al. "Phase I study of weekly nab-paclitaxel plus carboplatin and concurrent thoracic radiotherapy in elderly patients with unresectable locally advanced non-small cell lung cancer." Investigational new drugs vol. 40,1 (2022): 106-114. doi: https://doi.org/10.1007/s10637-021-01155-w
Omori S, Harada H, Mori K, Hisamatsu Y, Tsuboguchi Y, Yoshioka H, Morinaga R, Daga H, Kurata T, Takahashi T. Phase I study of weekly nab-paclitaxel plus carboplatin and concurrent thoracic radiotherapy in elderly patients with unresectable locally advanced non-small cell lung cancer. Invest New Drugs. 2022 Feb;40(1):106-114. doi: 10.1007/s10637-021-01155-w. Epub 2021 Sep 08. PMID: 34495421.
Copy Download .nbib Format: NLM
MYC-PDL1 axis reduces sensitivity to nivolumab in recurrent head and neck squamous cell carcinoma.

Oral oncology

Noji R, Kano Y, Hirai H, Onishi I, Nishii N, Yoshimura R, Miyake S, Ikeda S, Harada H.
PMID: 34896892
Oral Oncol. 2021 Dec 09;124:105666. doi: 10.1016/j.oraloncology.2021.105666. Epub 2021 Dec 09.

Patients with recurrent or metastatic squamous cell carcinoma of the head and neck (R/M HNSCC) have a poor prognosis. Recently, the use of immune checkpoint inhibitors (ICIs) for drug treatment has been expanding . However, the response rate to...

Cite
Noji R, Kano Y, Hirai H, et al. MYC-PDL1 axis reduces sensitivity to nivolumab in recurrent head and neck squamous cell carcinoma. Oral Oncol. 2021;124:105666doi: 10.1016/j.oraloncology.2021.105666.
Noji, R., Kano, Y., Hirai, H., Onishi, I., Nishii, N., Yoshimura, R., Miyake, S., Ikeda, S., & Harada, H. (2021). MYC-PDL1 axis reduces sensitivity to nivolumab in recurrent head and neck squamous cell carcinoma. Oral oncology, 124105666. https://doi.org/10.1016/j.oraloncology.2021.105666
Noji, Rika, et al. "MYC-PDL1 axis reduces sensitivity to nivolumab in recurrent head and neck squamous cell carcinoma." Oral oncology vol. 124 (2021): 105666. doi: https://doi.org/10.1016/j.oraloncology.2021.105666
Noji R, Kano Y, Hirai H, Onishi I, Nishii N, Yoshimura R, Miyake S, Ikeda S, Harada H. MYC-PDL1 axis reduces sensitivity to nivolumab in recurrent head and neck squamous cell carcinoma. Oral Oncol. 2021 Dec 09;124:105666. doi: 10.1016/j.oraloncology.2021.105666. Epub 2021 Dec 09. PMID: 34896892.
Copy Download .nbib Format: NLM
Showing 1993 to 1995 of 1995 entries